CN116867910A - 生物标志物 - Google Patents

生物标志物 Download PDF

Info

Publication number
CN116867910A
CN116867910A CN202180078581.9A CN202180078581A CN116867910A CN 116867910 A CN116867910 A CN 116867910A CN 202180078581 A CN202180078581 A CN 202180078581A CN 116867910 A CN116867910 A CN 116867910A
Authority
CN
China
Prior art keywords
subject
nafld
arld
gene
foxo1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180078581.9A
Other languages
English (en)
Chinese (zh)
Inventor
马修·霍尔
彼得·坎贝尔
史丹尼·吴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
Genome Research Ltd
Original Assignee
Cambridge Enterprise Ltd
Genome Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Ltd, Genome Research Ltd filed Critical Cambridge Enterprise Ltd
Publication of CN116867910A publication Critical patent/CN116867910A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202180078581.9A 2020-09-23 2021-09-23 生物标志物 Pending CN116867910A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2015056.1 2020-09-23
GBGB2015056.1A GB202015056D0 (en) 2020-09-23 2020-09-23 Biomarkers
PCT/GB2021/052469 WO2022064198A1 (en) 2020-09-23 2021-09-23 Biomarkers

Publications (1)

Publication Number Publication Date
CN116867910A true CN116867910A (zh) 2023-10-10

Family

ID=73139042

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180078581.9A Pending CN116867910A (zh) 2020-09-23 2021-09-23 生物标志物

Country Status (6)

Country Link
US (1) US20230348983A1 (https=)
EP (1) EP4217507A1 (https=)
JP (1) JP2023543763A (https=)
CN (1) CN116867910A (https=)
GB (1) GB202015056D0 (https=)
WO (1) WO2022064198A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250028934A1 (en) * 2023-07-17 2025-01-23 The Toronto-Dominion Bank Systems and methods for time series prediction using multi-stage computation
US20250263702A1 (en) * 2024-02-19 2025-08-21 Flagship Pioneering Innovations Vii, Llc Rnai agents targeting cideb and related methods
WO2025230979A1 (en) * 2024-04-30 2025-11-06 Flagship Pioneering Innovations Vii, Llc Tnfaip3-targeted compositions and related methods
WO2026038054A2 (en) * 2024-08-15 2026-02-19 Genome Research Limited Novel companion diagnostic method

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009971A1 (ja) 2003-07-24 2005-02-03 Astellas Pharma Inc. キノロン誘導体又はその塩
EP2310504A1 (en) * 2008-07-03 2011-04-20 Santaris Pharma A/S Rna antagonist compounds for the inhibition of expression of mitochondrial glycerol-3-phosphate acyltransferase 1 (mtgpat1)
EP2475781B1 (en) * 2009-09-11 2017-10-25 The Chinese University Of Hong Kong Methods for assessing liver pathologies
JP2018169277A (ja) * 2017-03-29 2018-11-01 国立大学法人神戸大学 炎症性関連病態を伴う非アルコール性脂肪性肝疾患のバイオマーカー
US11808772B2 (en) * 2017-07-19 2023-11-07 Bio-Rad Europe Gmbh Biomarker combinations to simultaneously evaluate non-alcoholic steatohepatitis and hepatic fibrosis status
IT201800006129A1 (it) * 2018-06-08 2019-12-08 Uso dello SNP rs17618244 come marcatore predittivo nella NAFLD.
WO2020044497A1 (ja) * 2018-08-30 2020-03-05 国立大学法人 東京大学 Ｎａｆｌｄ又はｎａｓｈの検出又はリスクの予測方法、ｎａｆｌｄ又はｎａｓｈを検出するための診断薬キット、対象における肝線維化の進行度の判定方法、及び対象における肝線維化の進行度を判定するための診断薬キット

Also Published As

Publication number Publication date
JP2023543763A (ja) 2023-10-18
EP4217507A1 (en) 2023-08-02
WO2022064198A1 (en) 2022-03-31
US20230348983A1 (en) 2023-11-02
GB202015056D0 (en) 2020-11-04

Similar Documents

Publication Publication Date Title
Ng et al. Convergent somatic mutations in metabolism genes in chronic liver disease
Sammut et al. Multi-omic machine learning predictor of breast cancer therapy response
Baharlou et al. Mass cytometry imaging for the study of human diseases—applications and data analysis strategies
Cox et al. Comparative systems biology of human and mouse as a tool to guide the modeling of human placental pathology
CN116867910A (zh) 生物标志物
JP7340021B2 (ja) 予測腫瘍遺伝子変異量に基づいた腫瘍分類
Matchett et al. Spatial genomics: mapping human steatotic liver disease
Vaidya et al. DNA methylation entropy as a measure of stem cell replication and aging
JP2019076096A (ja) 目的遺伝子発現の線形結合を用いた細胞信号伝達経路活性の評価
US20200190594A1 (en) Investigating tumoral and temporal heterogeneity through comprehensive -omics profiling in patients with metastatic triple negative breast cancer
JP2022505295A (ja) ヒト腫瘍のがん細胞における分子活性を定量化するための方法
Hynds et al. Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models
CN118660974A (zh) 细胞游离dna的单分子全基因组突变谱和片段谱
CN113853444A (zh) 癌症患者生存率的预测方法
Xu et al. Comprehensive analysis of the expression and prognosis for S100 in human ovarian cancer: A STROBE study
Moreno-Rubio et al. Clinical-pathological and molecular characterization of long-term survivors with advanced non-small cell lung cancer
US20240360508A1 (en) Use of circulating cell-free methylated dna to detect tissue damage
Patil et al. Medicine-A Novel Approach for Oral Cancer Management
Lin et al. LncRNA DIRC1 is a novel prognostic biomarker and correlated with immune infiltrates in stomach adenocarcinoma
Hynds et al. Genomic evolution of non-small cell lung cancer patient-derived xenograft models
JP2025522347A (ja) 微小残存病変を検出するための技法
Yakubovsky et al. A spatial atlas of the healthy human liver from live donors
CN116286895B (zh) Ror2突变体及其应用
US20250327132A1 (en) Lung Cancer-Related Biomarkers and Methods of Using the Same
Graham Identifying individuals at-risk of developing oesophageal adenocarcinoma through symptom, risk factor and salivary biomarker analysis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination